Home > Boards > US OTC > Basic Materials > Bioxytran Inc. (BIXT)

We are seeing very significant advancements being reported

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ProfitScout Member Profile
 
Followed By 123
Posts 14,177
Boards Moderated 12
Alias Born 04/03/02
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2020 2:35:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2020 4:01:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 2:40:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2020 4:27:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2019 7:53:53 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/25/2019 5:09:27 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 1:20:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 3:09:24 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 3:36:26 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 11/5/2019 1:51:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2019 9:14:38 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 2:57:37 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 3:55:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 3:33:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 9:03:15 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:51:25 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:49:39 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:47:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/29/2019 1:30:50 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 2:47:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2019 9:40:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/26/2019 5:23:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2019 4:26:45 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/13/2019 6:25:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/1/2019 10:09:20 AM
ProfitScout   Thursday, 05/23/19 10:58:09 AM
Re: StockHighAlert- post# 456
Post # of 505 
We are seeing very significant advancements being reported from the BIXT team in critical medical situations that involve oxygen supply to vital organs.

CEO David Platt explains it well here:

“Measuring the level of tissue oxygenation in diseases and surgical procedures could have a profound effect in clinical research” said Dr David Platt, CEO of Bioxytran. “In the past, researchers trying to prove the efficacy of a procedure on a vital organ like the brain had to rely on surrogate markers such as cognitive tests which require large patient populations and relatively subjective tests. With the advent of the FDA approved MDX Viewer, researchers can now accelerate their studies using the TMS biomarker and likely save a lot of money in the process. Tissue oxygenation levels are also important in tissue regeneration, stem cell transplantation, tissue transplantation, and tissue viability. The licensing opportunities in this area are boundless. Bioxytran’s initial focus will be for patients of a stroke, Acute Respiratory Deficiency Syndrome (ARDS), sepsis, and heart failure. The stroke market is estimated at 900,000 annually. Since there is an unmet medical need in the stroke indication, Bioxytran will be primarily focusing its efforts in advancing BXT-25 through the clinical trials.”



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist